LISURIDE
( DrugBank: Lisuride / KEGG DRUG: Lisuride )
2 diseases
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 9 of 9 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2010-020769-25-FR (EUCTR) | 10/08/201020100810 | 09/07/201020100709 | Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa ... | Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa ... | Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10034006;Term: Parkinson's d ... | Trade Name: DUODOPA INN or Proposed INN: LEVODOPA/CARBIDOPA INN or Proposed INN: LEVODOPA/BENZERASIDE INN or Proposed INN: PERGOLIDE INN or Proposed INN: LISURIDE INN or Proposed INN: BROMOCRIPTINE INN or Proposed INN: ROPINIROLE INN or Proposed INN: PRAMIPEXOLE INN or Proposed INN: IPRONIAZID Other descriptive name: MOCLOBEMIDE INN or Proposed INN: AMANTADINE INN or Proposed INN: CLOZAPINE INN or Proposed INN: SELEGILINE INN or Proposed INN: RASAGILINE INN or Proposed INN: ENTACAPONE INN or Proposed INN: TOLCAPONE Trade Name: DUODOPA INN or Proposed INN: LEVODOPA/CARBIDOPA INN or Proposed INN: LEVODOPA/BENZERASIDE I ... | CHU de Poitiers | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
2 | EUCTR2006-003732-30-PL (EUCTR) | 27/03/200820080327 | 08/01/200820080108 | Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1 Transdermal Use of Lisuridein Early Parkinson´s Disease: A double blind, randomized, Placebo and Pra ... | Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1 Transdermal Use of Lisuridein Early Parkinson´s Disease: A double blind, randomized, Placebo and Pra ... | Early Parkinson's Disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease Early Parkinson's Disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson ... | Product Name: Lisuride TTS 10cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,088 INN or Proposed INN: PRAMIPEXOLE Product Name: Lisuride TTS 20cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,18 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,35 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,7 INN or Proposed INN: PRAMIPEXOLE Product Name: LisurideTTS 10cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,088 INN or Proposed ... | NeuroBiotec Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 350 | Germany;Italy;Poland | |||
3 | EUCTR2006-003732-30-IT (EUCTR) | 31/12/200720071231 | 13/02/200820080213 | Transdermal Use of Lisuride in Early ParkinsonŽs Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - Tulep I Transdermal Use of Lisuridein Early ParkinsonŽs Disease: A double blind, randomized, Placebo and Pra ... | Transdermal Use of Lisuride in Early ParkinsonŽs Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - Tulep I Transdermal Use of Lisuridein Early ParkinsonŽs Disease: A double blind, randomized, Placebo and Pra ... | Diagnosys of Early-stage idiopathic Parkinson's Disease for longest 1 year MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease Diagnosys of Early-stage idiopathic Parkinson's Disease for longest 1 year MedDRA version: 9.1;Level ... | Product Name: lisuride TTS INN or Proposed INN: Lisuride Trade Name: mirapexin INN or Proposed INN: Pramipexole Product Name: lisurideTTS INN or Proposed INN: Lisuride Trade Name: mirapexin INN or Proposed INN: Pram ... | NEUROBIOTEC GMBH | NULL | Not Recruiting | Female: yes Male: yes | 350 | Germany;Italy;Poland | |||
4 | EUCTR2006-003732-30-DE (EUCTR) | 31/01/200720070131 | 29/11/200620061129 | Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1 Transdermal Use of Lisuridein Early Parkinson´s Disease: A double blind, randomized, Placebo and Pra ... | Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1 Transdermal Use of Lisuridein Early Parkinson´s Disease: A double blind, randomized, Placebo and Pra ... | Early Parkinson's Disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease Early Parkinson's Disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson ... | Product Name: Lisuride TTS 10cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,088 INN or Proposed INN: PRAMIPEXOLE Product Name: Lisuride TTS 20cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,18 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,35 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,7 INN or Proposed INN: PRAMIPEXOLE Product Name: LisurideTTS 10cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,088 INN or Proposed ... | Axxonis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 350 | Germany;Italy;Poland | |||
5 | EUCTR2005-001006-12-CZ (EUCTR) | 06/09/200620060906 | 24/08/200620060824 | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ... | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ... | Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment. MedDRA version: 9.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to co ... | Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- erg Product Name: Lisparin INN or Proposed INN: LisurideHydrogenmaleate Other descriptive name: 3- (9,10- ... | Axxonis Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2;Phase 3 | Czech Republic;Austria;Germany;Italy | ||
6 | NCT00408915 (ClinicalTrials.gov) | July 200620060700 | 5/12/200620061205 | Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion | Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficac ... | Parkinson's Disease | Drug: Continuous Subcutaneous Lisuride Infusion | Axxonis Pharma AG | NULL | Completed | 18 Years | 75 Years | Both | 60 | Phase 3 | Germany |
7 | EUCTR2005-001006-12-AT (EUCTR) | 02/04/200620060402 | 28/02/200620060228 | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ... | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ... | Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment. Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to co ... | Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate Trade Name: Sifrol, 0,35 mg Tablette Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Trade Name: Sifrol, 0,70 mg Tablette Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Trade Name: Cabaseril, 1,0 mg Tablette Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea Trade Name: Cabaseril, 2,0 mg Tablette Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- Product Name: Lisparin INN or Proposed INN: LisurideHydrogenmaleate Other descriptive name: 3- (9,10- ... | Axxonis Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Germany;Czech Republic;Italy;Austria | ||
8 | EUCTR2005-001006-12-DE (EUCTR) | 09/03/200620060309 | 05/09/200620060905 | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ... | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ... | Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment. MedDRA version: 9.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to co ... | Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- erg Product Name: Lisparin INN or Proposed INN: LisurideHydrogenmaleate Other descriptive name: 3- (9,10- ... | Axxonis Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2;Phase 3 | Czech Republic;Austria;Germany;Italy | ||
9 | NCT00089622 (ClinicalTrials.gov) | August 4, 200420040804 | 6/8/200420040806 | Lisuride Patch to Treat Parkinson's Disease | Transcutaneous Lisuride Therapy of Parkinson's Disease | Parkinson Disease | Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 40 Years | 80 Years | All | 40 | Phase 2 | United States |
86. 肺動脈性肺高血圧症
臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
Showing 1 to 2 of 2 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2012-001675-37-AT (EUCTR) | 07/08/201220120807 | 14/06/201220120614 | A Study to Investigate the Effects of Lisuride in addition to Conventional Treatment in Patients with Pulmonary Arterial Hypertension A Study to Investigate the Effects of Lisuridein addition to Conventional Treatment in Patients with ... | A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics of Lisuride Subcutaneous Infusion as Add-on to Conventional Treatment in Patients with Pulmonary Arterial Hypertension - Lis-Safe A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics ... | Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: LLT;Classification code 10036727;Term: P ... | Product Name: Lisuride INN or Proposed INN: Lisuride | Sinoxa Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 12 | Austria;Germany | |||
2 | EUCTR2012-001675-37-DE (EUCTR) | 24/07/201220120724 | 16/05/201220120516 | A Study to Investigate the Effects of Lisuride in addition to Conventional Treatment in Patients with Pulmonary Arterial Hypertension A Study to Investigate the Effects of Lisuridein addition to Conventional Treatment in Patients with ... | A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics of Lisuride Subcutaneous Infusion as Add-on to Conventional Treatment in Patients with Pulmonary Arterial Hypertension - Lis-Safe A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics ... | Pulmonary Arterial Hypertension MedDRA version: 16.0;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary Arterial Hypertension MedDRA version: 16.0;Level: LLT;Classification code 10036727;Term: P ... | Product Name: Lisuride INN or Proposed INN: Lisuride | Sinoxa Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 12 | Austria;Germany |